Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation

We recently noted that low doses of sorafenib and vorinostat interact in a synergistic fashion to kill carcinoma cells by activating CD95, and this drug combination is entering phase I trials. The present studies mechanistically extended our initial observations. Low doses of sorafenib and vorinosta...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Park, Margaret A., Zhang, Guo, Martin, Aditi Pandya, Hamed, Hossein, Mitchell, Clint, Hylemon, Philip B., Graf, Martin, Rahmani, Mohamed, Ryan, Kevin, Liu, Xiang, Spiegel, Sarah, Norris, James, Fisher, Paul B., Grant, Steven, Dent, Paul
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2008
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2674577/
https://ncbi.nlm.nih.gov/pubmed/18787411
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg